Who Is Kabir Nath? Chief Executive Officer of Compass Pathways
Chief executive officer of Compass Pathways navigating regulatory submissions and commercial strategy for psychedelic medicine.
Kabir Nath is the chief executive officer of Compass Pathways.
At Mind Medicine Law, we track the people building legal, evidence-based access to psychedelic medicine: the companies running the trials, the researchers and advocates behind them, and the officials who write and run the laws.
Nath spent a significant portion of his professional career in New Jersey and now guides Compass Pathways as it approaches regulatory review and commercial preparation for its psychedelic therapy.
Where Kabir Nath Is Now
- Current role: Chief executive officer
- Organization: Compass Pathways
- Known for: Stating Compass Pathways will 'go slow before we go fast' ahead of submitting its psychedelic therapy for regulatory review
- Recent news: Welcomed Kelley Boucher to the executive team ahead of a fourth-quarter NDA submission
Kabir Nath serves as the chief executive officer of Compass Pathways as the company prepares its psychedelic therapy for regulatory review (STAT).
Career Background
Nath spent a significant portion of his professional career in New Jersey (MarketScreener).
He stated that Compass Pathways is proud to call Jersey City home as the company enters its next phase of growth (MarketScreener).
Regulatory and Clinical Strategy
Speaking in Boston at the STAT Summit, Nath described the therapy as a major milestone for patients, providers, and Compass Pathways (STAT). He emphasized that a cautious rollout would be essential as the psychedelics field approaches its first potential FDA approval, stating that Compass Pathways will 'go slow before we go fast' ahead of submitting its psychedelic therapy for regulatory review.
Nath stated that Compass Pathways expects its treatment to be subject to an FDA risk evaluation and mitigation strategy and is investing in provider training (STAT).
In clinical trials, Nath stated that Compass intentionally separated psychotherapy from its trials, viewing the company's role as developing a drug rather than directing psychological care (STAT). He pointed out that an analysis of recorded treatment sessions revealed that approximately 80% of the time was spent in silence.
Treatment Data and Commercial Rollout
Nath stated that psilocybin has shown the potential for rapid and lasting improvements after only a handful of administrations (STAT). According to Nath, Compass's longer-term data indicates that responding patients can experience benefits lasting up to a year after two or three administrations.
Regarding commercialization, Nath acknowledged Johnson & Johnson's Spravato as a reference point for pricing while declining to commit to a specific pricing benchmark (STAT). He also stated that Compass has spent years working on reimbursement mechanisms for monitoring and is engaging with commercial insurers and CMS.
Ahead of the company's fourth-quarter NDA submission, Nath welcomed Kelley Boucher to the Compass executive team (StreetInsider).
Frequently asked questions
Who is Kabir Nath?
Kabir Nath is the chief executive officer of Compass Pathways (STAT).
What is Kabir Nath's stance on Compass Pathways' regulatory submission?
Nath stated that Compass Pathways will 'go slow before we go fast' ahead of submitting its psychedelic therapy for regulatory review, emphasizing that a cautious rollout is essential as the field approaches its first potential FDA approval (STAT).
How does Compass Pathways address psychotherapy in its clinical trials?
Nath stated that Compass intentionally separated psychotherapy from its clinical trials, viewing the company's role as developing a drug rather than directing psychological care, and noted that recorded sessions showed approximately 80% of the time was spent in silence (STAT).
What has Kabir Nath stated about psilocybin treatment outcomes?
Nath stated that psilocybin has shown potential for rapid and lasting improvements after a handful of administrations, with longer-term data indicating responding patients can experience benefits lasting up to a year after two or three administrations (STAT).
What pricing benchmark has Kabir Nath discussed for Compass's therapy?
Nath acknowledged Johnson & Johnson's Spravato as a reference point for pricing while declining to commit to a specific pricing benchmark (STAT).
Where has Kabir Nath spent a significant portion of his career?
Nath spent a significant portion of his professional career in New Jersey (MarketScreener).
Sources
General information compiled from the public reporting cited above, not medical or legal advice. Mention of a treatment, trial or bill is not a claim that it is safe, effective or legal where you live. Not endorsed by or affiliated with Kabir Nath or Compass Pathways. See more people in psychedelic medicine.